Protein aggregation in disease: A role for folding intermediates forming specific multimeric interactions

Journal of Clinical Investigation

Volumn 110, Issue 9, 2002, Pages 1221-1232

  Horwich, Arthur ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; AMYLOID; AMYLOID BETA PROTEIN; CHAPERONIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; BIOSYNTHESIS; CELL INCLUSION; CONCENTRATION RESPONSE; CYTOPATHOLOGY; DEGENERATIVE DISEASE; HEART AMYLOIDOSIS; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; MUTAGENESIS; NEUROPATHOLOGY; POLYMERIZATION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; PROTEIN SYNTHESIS; REVIEW; SICKLE CELL ANEMIA; THERMODYNAMICS; THERMOSTABILITY;

EID: 0036841958     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0216781     Document Type: Review

References (80)

1. Weatherall, D.J., Clegg, J.B., Higgs, D.R., and Wood, W.G. 2001. The hemoglobinopathies. In Metabolic and Molecular Bases of Inherited Disease. C. Scriver, A. Beaudet, D. Valle, and W. Sly, editors. McGraw-Hill. New York, New York, USA. 4571-4636.
2. 1-antitrypsin deficiency: Role of autophagy and mitochondrial injury in response to aggregated protein in the endoplasmic reticulum. J. Clin. Invest. In press.
3. 1-antitrypsin deficiency. In Metabolic and Molecular Bases of Inherited Disease. C. Scriver, A. Beaudet, D. Valle, and W. Sly, editors. McGraw-Hill. New York, New York, USA. 5559-5584.
4. Selkoe, D.J. 2002. Deciphering the genesis and fate of amyloid-β protein yields novel therapies for Alzheimer disease. J. Clin. Invest. In press.
5. Selkoe, D. 1997. Cellular and molecular biology of the beta-amyloid precursor protein and Alzheimer's disease. In The Molecular and Genetic Basis of Neurological Disease. R.N. Rosenberg, S.B. Prusiner, S. DiMauro, and R.L. Barchi, editors. Butterworth-Heinemann, Boston, Massachusetts, USA. 601-611.
6. DeArmond, S.J., and Prusiner, S.B. 1997. Molecular neuropathology of prion diseases. In The Molecular and Genetic Basis of Neurological Disease. R.N. Rosenberg, S.B. Prusiner, S. DiMauro, and R.L. Barchi, editors. Butterworth-Heinemann, Boston, Massachusetts, USA. 145-163.
7. DiFiglia, M., et al. 1997. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 277:1990-1993.
8. Scherzinger, E., et al. 1997. Huntintin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell. 90:549-558.
9. Conway, K.A., Harper, J.D., and Lansbury, P.T. 2000. Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry. 39:2552-2563.
10. Serpell, L.C., Berriman, J., Jakes, R., Goedert, M., and Crowther, R.A. 2000. Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation. Proc. Natl. Acad. Sci. USA. 97:4897-4902.
11. Anfinsen, C.B. 1973. Principles that govern the folding of protein chains. Science. 181:223-230.
12. Fersht, A.R. 1995. Characterizing transition states in protein folding: An essential step in the puzzle. Curr. Opin. Struct. Biol. 5:79-84.
13. Baker, D. 2000. A surprising simplicity to protein folding. Nature. 405:39-42.
14. Kim, P.S., and Baldwin, R.L. 1990. Intermediates in the folding reactions of small proteins. Annu. Rev. Biochem. 59:631-660.
15. Silow, M., Tan, Y.-J., Fersht, A.R., and Oliveberg, M. 1999. Formation of short-lived protein aggregates directly from the coil in two-state folding. Biochemistry. 38:13006-13012.
16. London, J., Skrzynia, C., and Goldberg, M.E. 1974. Renaturation of Escherichia coli tryptophanase after exposure to 8 M urea. Eur. J. Biochem. 47:409-415.
17. Zettlmeissl, G., Rudolph, R., and Jaenicke, R. 1979. Reconstitution of lactic dehydrogenase. Noncovalent aggregation vs. reactivation. Biochemistry. 18:5567-5571.
18. Mitraki, A., Betton, J.-M., Desmadril, M., and Yon, J.M. 1987. Quasi-irreversibility in the unfolding-refolding transition of phosphoglycerate kinase induced by guanidine hydrochloride. Eur. J. Biochem. 163:29-34.
19. Brems, D.N. 1988. Solubility of different folding conformers of bovine growth hormone. Biochemistry. 27:4541-4546.
20. Steinbacher, S., et al. 1994. Crystal structure of P22 tailspike protein: Interdigitated subunits in a thermostable trimer. Science. 265:383-386.
21. Haase-Pettingell, C.A., and King, J. 1988. Formation of aggregates from a thermolabile in vivo folding intermediate in P22 tailspike maturation. J. Biol. Chem. 263:4977-4983.
22. King, J., Haase-Pettingell, C., Robinson, A.S., Speed, M., and Mitraki, A. 1996. Thermolabile folding intermediates: Inclusion body precursors and chaperonin substrates. FASEB J. 10:57-66.
23. Mitraki, A., Fane, B., Haase-Pettingell, C., Sturtevant, J., and King, J. 1991. Global suppression of protein folding defects and inclusion body formation. Science. 253:54-58.
24. Gordon, C.L., and King, J. 1993. Temperature-sensitive mutations in the phage P22 coat protein which interfere with polypeptide chain folding. J. Biol. Chem. 268:9358-9368.
25. Speed, M.A., Wang, D.I.C., and King, J. 1996. Specific aggregation of partially folded polypeptide chains: The molecular basis of inclusion body composition. Nat. Biotechnol. 14:1283-1287.
26. Bennett, M.J., Choe, S., and Eisenberg, D. 1994. Domain swapping: Entangling alliances between proteins. Proc. Natl. Acad. Sci. USA. 91:3127-3131.
27. Bennett, MJ., Schlunegger, M.P., and Eisenberg, D. 1995. 3D domain swapping: A mechanism for oligomer assembly. Protein Sci. 4:2455-2468.
28. 1-antitrypsin polymerization and the serpinopath: pathobiology and prospects for therapy. J. Clin. Invest. In press.
29. 1-antitrypsin accumulation in the liver. Nature. 357:605-607.
30. Pelham, H.R. 1986. Speculations on the functions of the major heat shock and glucose-regulated proteins. Cell. 46:959-961.
31. Bukau, B., and Horwich, A.L. 1998. The Hsp70 and Hsp60 chaperone machines. Cell. 92:351-366.
32. Cheng, M.Y., et al. 1989. Mitochondrial heat-shock protein Hsp60 is essential for assembly of proteins imported into yeast mitochondria. Nature. 337:620-625.
33. Goloubinoff, P., Christeller, J.T., Gatenby, A.A., and Lorimer, G.H. 1989. Reconstitution of active dimeric ribulose bisphosphate carboxylase from an unfolded state depends on two chaperonin proteins and MgATP. Nature. 342:884-889.
34. Martin, J., et al. 1991. Chaperonin-mediated protein folding at the surface of groEL through a "molten globule"-like intermediate. Nature. 352:36-42.
35. Ranson, N.A., Dunster, N.J., Burston, S.G., and Clarke, A.R. 1995. Chaperonins can catalyze the reversal of early aggregations steps when a protein misfolds. J. Mol. Biol. 250:581-586.
36. Braig, K., et al. 1994. The crystal structure of the bacterial chaperonin GroEL at 2.8 Å. Nature. 371:578-586.
37. Grantcharova, V., Alm, E.J., Baker, D., and Horwich, A.L. 2001. Mechanisms of protein folding. Curr. Opin. Struct. Biol. 11:70-82.
38. Xu, Z., Horwich, A.L., and Sigler, P.B. 1997. The crystal structure of the asymmetric GroEL-GroES-(ADP)-chaperonin complex. Nature. 388:741-750.
39. Gordon, C.L., Sather, S.K., Casjens, S., and King, J. 1994. Selective in vivo rescue by GroEL-ES of thermolabile folding intermediate to phage P22 structural proteins. J. Biol. Chem. 269:27941-27951.
40. Glover, J.R., and Lindquist, S. 1998. Hsp104, Hsp70, and Hsp40: A novel chaperone system that rescues previously aggregated proteins. Cell. 94:73-82.
41. Parsell, D.A., Kowal, A.S., Singer, M.A., and Lindquist, S. 1994. Protein disaggregation mediated by heat-shock protein Hsp104. Nature. 372:475-478.
42. Kaufman, R. 2002. Orchestrating the unfolded protein response in health and disease. J. Clin. Invest. In press.
43. Tu, B.P., Ho-Schleyer, S.C., Travers, KJ., and Weissman, J.S. 2000. Biochemical basis of oxidative protein folding in the endoplasmic reticulum. Science. 290:1571-1574.
44. Tsai, B., Rodighiero, C., Lencer, W.I., and Rapoport, T.A. 2001. Protein disulfide isomerase acts as a redox-dependent chaperone to unfold cholera toxin. Cell. 104:937-948.
45. Helenius, A., and Aebi, M. 2001. Intracellular functions of N-linked glycans. Science. 291:2364-2369.
46. Cohen, A.S., and Calkins, E. 1959. Electron microscopic observation on a fibrous component in amyloid of diverse origins. Nature. 183:1202-1203.
47. Shirahama, T., and Cohen, A.S. 1967. High-resolution electron microscopic analysis of the amyloid fibril. J. Cell Biol. 33:679-708.
48. Eanes, E.D., and Glenner, G.G. 1968. X-ray diffraction studies on amyloid filaments. J. Histochem. Cytochem. 16:673-677.
49. Bonar, L., Cohen, A.S., and Skinner, M.M. 1969. Characterization of the amyloid fibril as a cross-β protein. Proc. Soc Exp. Biol. Med. 131:1373-1375.
50. Glenner, G.G., Harbaugh, J., Ohms, J.I., Harada, M., and Cuatrecasas, P. 1970. An amyloid protein: The amino-terminal variable fragment of an immunoglobulin light chain. Biochem. Biopbys. Res. Commun. 41:1287-1289.
51. Glenner, G.G. 1980. Amyloid deposits and amyloidosis: The β-fibrilloses. N. Engl. J. Med. 302:1283-1292
52. Kelly, J.W. 1996. Alternative conformations of amyloidogenic proteins govern their behaviour. Curr. Opin. Struct. Biol. 6:11-17.
53. Fandrich, M., Fletcher, M.A., and Dobson, C.M. 2001. Amyloid fibrils from muscle myloglobin. Nature. 410:165-166.
54. Dobson, C.M. 1999. Protein misfolding, evolution and disease. Trends Biochem. Sci. 24:329-332.
55. Blake, C., and Serpell, L. 1996. Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous β-sheet helix Structure. 4:989-998.
56. Jimenez, J.L., et al. 1999. Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO J. 18:815-821.
57. Glover, J.R., et al. 1997. Self-seeded fibers formed by Sup35, the protein determinant of [PS1], a heritable prion-like factor of S. cerevisiae. Cell. 89:811-819.
58. Hurle, M.R., Helms, L.R., Li, L., Chan, W., and Wetzel, R. 1994. A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc. Natl. Acad Sci. USA. 91:5446-5450.
59. Booth, D.R., et al. 1997. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature. 385:787-793.
60. Lai, Z., Colon, W., and Kelly, J.W. 1996. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry. 35:6470-6482.
61. Colon, W., and Kelly, J.W. 1992. Partial denaturation off transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry. 31:8654-8660.
62. McCutchen, S.L., Lai, Z., Miroy, G.J., Kelly, J.W., and Colon, W. 1995. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry. 34:13527-13536.
63. Hammarstrom, P., Schneider, F., and Kelly, J.W. 2001. Trans-suppression of misfolding in an amyloid disease. Science. 293:2459-2462.
64. Jiang, X., et al. 2001. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry. 40:11442-11452.
65. Liu, K., Cho, H.S., Lashuel, H.A., Kelly, J.W., and Wemmer, D.E. 2000. A glimpse of a possible amyloidogenic intermediate of transthyretin. Nat. Struct. Biol. 7:754-757.
66. Jiang, X., Buxbaum, J.N., and Kelly, J.W. 2001. The V122I cardiomyophathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc. Natl. Acad. Sci. USA. 98:14943-14948.
67. Swietnicki, W., Petersen, R.B., Gambetti, P., and Surewicz, W.K. 1998. Familial mutations and the thermodynamic stability of the recombinant human prion protein. J. Biol. Chem. 273:31048-31052.
68. Liemann, S., and Glockshuber, R. 1999. Influence of amino acid substitutions related to inherited human prion diseases on the thermodynamic stability of the cellular prion protein. Biochemistry. 38:3258-3267.
69. Baskakov, I.V., Legname, G., Prusiner, S.B., and Cohen, F.E. 2001. Folding of prion protein to its native alpha-helical conformation is under kinetic control. J. Biol. Chem. 276:19687-19690.
70. Harper, J.D., and Lansbury, P.T. 1997. Models of amyloid seeding in Alzheimer's disease and scrapie. Annu. Rev. Biochem. 66:385-407.
71. Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., and Formigli, L. 2002. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 416:507-511.
72. Walsh, D.M., et al. 2002. Naturally secreted oligomers of amyloid protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 416:535-539.
73. Chiti, F., et al. 2002. Kinetic partitioning of protein folding and aggregation. Nat. Struct. Biol. 9:137-143.
74. Perutz, M.F., Johnson, T., Suzuki, M., and Finch, J.T. 1994. Glutamine repeats as polar zippers: Their possible role in inherited neurodegenerative diseases. Proc. Natl. Acad. Sci. USA. 91:5355-5358.
75. Bence, N.F., Sampat, R.M., and Kopito, R.R. 2001. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 292:1552-1555.
76. Prusiner, S.B. 2001. Shattuck lecture: Neurodegenerative diseases and prions. N. Engl. J. Med. 244:1516-1526.
77. Miroy, G.J., et al. 1996. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Natl. Acad. Sci. USA. 93:15051-15056.
78. Klabunde, T., et al. 2000. Rational design of potent human transthyretin amyloid disease inhibitors. Nat. Struct. Biol. 7:312-321.
79. Korth, C., May, B.C.H., Cohen, F.E., and Prusiner, S.B. 2001. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl. Acad. Sci. USA. 98:9836-9841.
80. Dill, K.A., and Chan, H.S. 1997. From Levinthal to pathways to funnels. Nat. Struct. Biol. 4:10-19.